Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

51
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
51
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

258
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
258
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

245
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in pediatric patients with functional constipation" [Contemp. Clin. Trials Commun. 33 (2023) 101144].

Contemporary clinical trials communications·2024
Same author

Diagnostic Considerations in Pediatric Inflammatory Bowel Disease Management.

Gastroenterology & hepatology·2023
Same author

The Utility of Contrast Enhanced Ultrasound and Elastography in the Early Detection of Fibro-Stenotic Ileal Strictures in Children with Crohn's Disease.

Pediatric gastroenterology, hepatology & nutrition·2023
Same author

Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in pediatric patients with functional constipation.

Contemporary clinical trials communications·2023
Same author

Seizure During Infliximab Infusion in a Child With Crohn's Disease: An Illustration of a Neurologic Adverse Event Associated With Drug Antibodies.

JPGN reports·2023
Same author

Early Onset Colorectal Adenocarcinoma in a 15-Year-Old with Pathogenic Germline Mutations in APC and MLH1: A Case Report.

Clinical colorectal cancer·2021

Related Experiment Video

Updated: Mar 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K

A Physician's Guide to Azathioprine Metabolite Testing.

Carmen Cuffari1

  • 1Dr. Cuffari is Associate Professor of Pediatrics at The Johns Hopkins School of Medicine, Division of Pediatric Gastroenterology, in Baltimore, Md.

Gastroenterology & Hepatology
|February 18, 2017
PubMed
Summary

Individualizing azathioprine (AZA) dosage based on thiopurine methyl transferase (TPMT) activity can optimize inflammatory bowel disease treatment. Monitoring AZA dosing by TPMT activity aims to achieve therapeutic 6-thioguanine levels and reduce side effects.

Keywords:
6-mercaptopurineAzathioprineIBDmetabolitestherapy

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.8K
Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

14.4K

Related Experiment Videos

Last Updated: Mar 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.8K
Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

14.4K

Area of Science:

  • Pharmacogenomics
  • Gastroenterology
  • Clinical Pharmacology

Background:

  • 6-Mercaptopurine (6-MP) and azathioprine (AZA) are effective for inflammatory bowel disease remission.
  • Genetic variations in thiopurine methyl transferase (TPMT) activity affect patient response to these drugs.
  • TPMT activity influences 6-MP metabolism, impacting therapeutic efficacy and side effect profiles.

Purpose of the Study:

  • To explore the role of individualized azathioprine (AZA) dosing strategies based on thiopurine methyl transferase (TPMT) activity in inflammatory bowel disease (IBD) management.
  • To assess the potential of tailoring AZA dosage to TPMT enzyme activity to improve clinical response and minimize adverse events.
  • To investigate the target therapeutic levels of 6-thioguanine (6-TGn) nucleotide metabolites for optimizing AZA therapy.

Main Methods:

  • Review of recent studies on AZA dosing adjustments according to TPMT enzyme activity.
  • Analysis of proposed therapeutic ranges for erythrocyte 6-thioguanine (6-TGn) nucleotide metabolites.
  • Evaluation of the impact of genetic polymorphism in TPMT on 6-MP metabolism and drug response.

Main Results:

  • Patients with intermediate TPMT activity may benefit from a low initial AZA dose (1 mg/kg) with careful monitoring.
  • Individuals with very high TPMT activity (>15 U/mL) might require higher AZA doses (>2 mg/kg) but risk refractoriness.
  • Achieving therapeutic erythrocyte 6-TGn levels (235-260 pmol/8×10^8 RBCs) is key for individualized AZA dosing.

Conclusions:

  • Individualized AZA dosing guided by TPMT activity is a promising strategy for IBD patients.
  • This approach aims to enhance treatment efficacy and reduce the risk of adverse effects like bone marrow suppression.
  • Further prospective trials are necessary to confirm the widespread clinical applicability of these drug monitoring strategies.